Sheet 1 of 2

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.: 117-473

SERIAL NO.: 10/650,074

APPLICANT: ARTHUR, M. et al

FILING DATE: August 28, 2003

GROUP:

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		6,197,749	3/2001	Hamuro et al			
		2002/0037934	3/2002	Amin et al			
		6,107,273	8/2000	Jameson et al			

FOREIGN PATENT DOCUMENTS

		DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
		WO 91/13622	9/1991	WIPO				
		WO 93/12789	7/1993	WIPO				
		WO 97/32585	9/1997	WIPO				
		WO 02/18330	3/2002	WIPO				

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

		Hadengue et al, "Beneficial Hemodynamic Effects of Ketanserin in Patients with Cirrhosis: Possible Role of Serotonergic Mechanisms in Portal Hypertension", Hepatology 7(4):644-647 (1987)
		Lebrec, D., "Portal Hypertension: Serotonin and Pathogenesis", Cardiovascular Drugs and Therapy 4:33-35 (1990)
		Pomier-Layrargues et al, "Combined Treatment of Portal Hypertension with Ritanserin and Propranolol in Conscious and Unrestrained Cirrhotic Rats", Hepatology 15:878-882 (1992)
		Wright et al, "Gliotoxin Initiates the Apoptosis of Rat and Human Hepatic Stellate Cells – A Mechanism for Modulating the Progression and Resolution of Liver Fibrosis", Hepatology 34(4):340A (2001) – AASLD Abstract No. 671 – XP009017657
		Wright et al, "Gliotoxin Stimulates the Apoptosis of Human and Rat Stellate Cells and Enhances the Resolution of Liver Fibrosis in Rats", Gastroenterology 121(3):685-698 (2001)
		Dekel et al, "Gliotoxin Ameliorates Development of Fibrosis and Cirrhosis in a Thioacetamide Rat Model", Hepatology 34(4):516A (2001) – AASLD Abstract No. 1377 – XP009022978
		Wright et al, "Gliotoxin stimulates apoptosis in cultured rat hepatic stellate cells", 30:98 (1999) (EASL Abstract P/C04/011) – Abstract, XP009022977
		Dekel et al, "Gliotoxin Ameliorates Development of Fibrosis and Cirrhosis in a Thioacetamide Rat Model", Digestive Diseases and Sciences 48(8):1642- 1647 (2003)
		Matsui et al, "Protective effect of sulfasalazine on hepatic ischemia-reperfusin injury in rats", Japanese Journal of Pharmaceology 88:104P (2002) – Abstract, XP009030945
		Oakley et al, "Sulfasalazine Inhibits NFKB Activity and Induces Apoptosis of Rat Hepatic Stellate Cells", Hepatology 36(4):486A (2002) – Abstract, XP009030944
		Alcolado et al, "Pathogenesis of liver fibrosis", Clinical Science 92:103-112 (1997)

*Examiner | Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

03/14/06

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.: 117-473

SERIAL NO.: 10/650,074

APPLICANT: ARTHUR, M. et al.

FILING DATE: August 28, 2003

GROUP:

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Elsharkawy et al, "Persistent Activation of Nuclear Factor-κB in Cultured Rat Hepatic Stellate Cells Involves the Induction of Potentially Novel Rel-Like Factors and Prolonged Changes in the Expression of IκB Family Proteins", Hepatology 30(3):761-769 (1999)
	Friedman, Scott L., "The Cellular Basis of Hepatic Fibrosis", The New England Journal of Medicine 328:1828-1835 (1993)
	Friedman, Scott L., "Molecular Regulation of Hepatic Fibrosis, an Integrated Cellular Response to Tissue Injury", The Journal of Biological Chemistry 274(4):2247-2250 (2000)
	Milani et al, "In Situ Hybridization for Procollagen Types I, III and IV mRNA in Normal and Fibrotic Rat Liver: Evidence for Predominant Expression in Nonparenchymal Liver Cells", Hepatology 10(1):84-92 (1989)
	Trim et al, "Hepatic Stellate Cells Express the Low Affinity Nerve Growth Factor Receptor p75 and Undergo Apoptosis in Response to Nerve Growth Factor Stimulation", American Journal of Pathology 156(4):1235-1243 (2000)
	Iredale et al, "Mechanisms of Spontaneous Resolution of Rat Liver Fibrosis", J. Clin. Invest. 102(3):538-549 (1998)
	Calès, P., "Apoptosis and liver fibrosis: antifibrotic strategies", Biomed. & Pharmacother. 52:259-263 (1998)
	Fischer et al, "Expression of the Peripheral-type Benzodiazepine Receptor and Apoptosis Induction in Hepatic Stellate Cells", Gastroenterology 120:1212-1226 (2001)
	Gressner, Axel M., "The Up-and-Down of Hepatic Stellate Cells in Tissue Injury: Apoptosis Restores Cellular Homeostasis", Gastroenterology 120(5):1285-1288 (2001)
	Gong et al, "Transformation-dependent Susceptibility of Rat Hepatic Stellate Cells to Apoptosis Induced by Soluble Fas Ligand", Hepatology 28(2):492-502 (1998)
	Iredale, John P., "Hepatic Stellate Cell Behavior during Resolution of Liver Injury", Seminars in Liver Disease 21(3):427-436 (2001)
	Issa et al, "Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors", Gut 48(4):548-557 (2001)
	Iwamoto et al, "Induction of apoptosis in rat hepatic stellate cells by disruption of integrin-mediated cell adhesion", J. Lab. Clin. Med. 134(1):83-89 (1999)
	Lang et al, "Nuclear factor κB in proliferation, activation, and apoptosis in rat hepatic stellate cells", Journal of Hepatology 33(1):49-58 (2000)
	Murphy et al, "Inhibition of Apoptosis of Activated Hepatic Stellate Cells by Tissue Inhibitor of Metalloproteinase-1 Is Mediated via Effects on Matrix Metalloproteinase Inhibition", The Journal of Biological Chemistry 277(13):11069-11076 (2002)
	Saile et al, "CD95/CD95L-Mediated Apoptosis of the Hepatic Stellate Cell", American Journal of Pathology 151(5):1265-1272 (1997)
	Saile et al, "Transforming Growth Factor β and Tumor Necrosis Factor α Inhibit Both Apoptosis and Proliferation of Activated Rat Hepatic Stellate Cells", Hepatology 30(1):196-202 (1999)
	Wright et al, "Gliotoxin Stimulates the Apoptosis of Rat and Human Hepatic Stellate Cells In Vitro", International Cells of the Hepatic Sinusoid 8:287-290 (2001)

*Examiner: [signature] Date Considered: 03/14/06

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

Sheet 1 of 1

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. 117-473

SERIAL NO. 10/650,074

APPLICANT ARTHUR, M. et al.

FILING DATE August 28, 2003

GROUP

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

		Ruddell et al, "Expression and Function of 5-Hydroxytryptamine 2 Receptors on the Surface of Rat Hepatic Stellate Cells", Hepatology 36(4):391 Part 2 Suppl. (2002) – AASLD Abstracts
		Oakley et al, "Sulfasalazine Inhibits NFKB Activity and Induces Apoptosis of Rat Hepatic Stellate Cells", Hepatology 36(4):1291 Part 2 Suppl. (2002) – AASLD Abstracts
		Mann et al, "The NFKB Inhibitor Sulfasalazine Enhances Recovery from CCL4 Induced Fibrosis: Therapeutic Implications", Hepatology 38(4):896 Suppl. 1 (2003) – AASLD Abstracts
		Oakley et al, "The Inhibitory IκBKINASE (IKK) Inhibitor Sulfasalazine Inhibits NFκB Activation and Induces Apoptosis in Activated Rat Hepatic Stellate Cells (HSC)", GUT 52(5):23 (2003) – BASL Abstracts
		Oakley et al, "Hepatocytes Express Nerve Growth Factor during Liver Injury", American Journal of Pathology 163(5):1849-1858 (2003)
		Ruddell et al, "Expression and Function of 5-Hydroxytryptamine$_2$ Receptors on the Surface of Rat Hepatic Stellate Cells", GUT 52(2):32 (2003) – BASL Abstracts

*Examiner [signature] Date Considered 03/14/06

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)